220 related articles for article (PubMed ID: 35614467)
1. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.
Rhodes K; Jenkins M; de Nigris E; Aurivillius M; Ouwens M
BMC Med Res Methodol; 2022 May; 22(1):150. PubMed ID: 35614467
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.
de Nigris E; Treharne C; Brighton N; Holmgren U; Walker A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2022; 17():2987-3000. PubMed ID: 36444374
[TBL] [Abstract][Full Text] [Related]
3. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
4. Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.
Singh D; Rabe KF; Martinez FJ; Krüll M; Jenkins M; Patel M; Dorinsky P
Respir Med; 2022 Jun; 197():106857. PubMed ID: 35512458
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
Muro S; Sugiura H; Darken P; Dorinsky P
Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
[TBL] [Abstract][Full Text] [Related]
6. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
Respir Med; 2019; 158():59-66. PubMed ID: 31605923
[TBL] [Abstract][Full Text] [Related]
7. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
[No Abstract] [Full Text] [Related]
8. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
[TBL] [Abstract][Full Text] [Related]
9. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Wedzicha JA; Decramer M; Ficker JH; Niewoehner DE; Sandström T; Taylor AF; D'Andrea P; Arrasate C; Chen H; Banerji D
Lancet Respir Med; 2013 May; 1(3):199-209. PubMed ID: 24429126
[TBL] [Abstract][Full Text] [Related]
10. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Aurivillius M; Reisner C; Dorinsky P;
N Engl J Med; 2020 Jul; 383(1):35-48. PubMed ID: 32579807
[TBL] [Abstract][Full Text] [Related]
11. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
12. Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS.
Martinez FJ; Ferguson GT; Bourne E; Ballal S; Darken P; Aurivillius M; Dorinsky P; Reisner C
Int J Chron Obstruct Pulmon Dis; 2021; 16():179-189. PubMed ID: 33542624
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives.
Mittmann N; Hernandez P; Mellström C; Brannman L; Welte T
Pharmacoeconomics; 2011 May; 29(5):403-14. PubMed ID: 21504240
[TBL] [Abstract][Full Text] [Related]
14. Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial.
Jackson D; Jenkins M; de Nigris E; Purkayastha D; Patel M; Ouwens M
Qual Life Res; 2024 Apr; 33(4):1029-1039. PubMed ID: 38206455
[TBL] [Abstract][Full Text] [Related]
15. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
16. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
19. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial.
Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Trivedi R; Jenkins M; Darken P; Aurivillius M; Dorinsky P
Respir Med; 2021; 185():106509. PubMed ID: 34171789
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.
Ichinose M; Nishimura M; Akimoto M; Kurotori Y; Zhao Y; de la Hoz A; Mishima M
Int J Chron Obstruct Pulmon Dis; 2018; 13():2147-2156. PubMed ID: 30034230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]